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2.1. Natural products in CNS-active drug discovery
Challenges and opportunities 
in silico
Discovery of novel leads 
Neuroactive leads 










2.2. The GABAA receptors 
Structure and pharmacology
via







In vivo GABAergic activity models
Caenorhabditis elegans Drosophila melanogaster
Danio rerio
Danio rerio





















2.3. Zebrafish as a model organism in drug discovery and development 
Danio rerio
2.3.1. Zebrafish development and life cycle 
Figure 2.3-1:






2.3.2. Advantages of zebrafish as a model organism 
Rapid life cycle and low-cost maintenance
Transparent embryos and larvae
In vivo
Genetic homology to humans
Multi-organ system similar to humans
Listeria monocytogenes Streptococcus
Mycobacterium marinum Edwardsiella tarda
in vivo
2.3.3. Zebrafish in drug discovery and development 
in vitro
in vivo








2.3.4. Rationale for neuroactive drug discovery with zebrafish 
in vitro





2.3.5. GABAA signaling system in zebrafish 
via























2.4. ADME profiling in neuroactive drug discovery 









In silico in vitro











in silico in vitro in vivo 
in silico 
in vitro in vivo 
2.4.2.2. In vitro membrane permeability studies 
In vitro 
Figure 2.4-1.
Cell-based intestinal barrier model





















In vitro in 
vivo
in vitro in vivo
in vitro
2.5. Bioanalysis 
2.5.1. Bioanalytical Method development 
Sample preparation 
LC-MS/MS instrument and detection optimization










3. Result and Discussion

3.1. HPLC-based activity profiling for GABAA receptor modulators in extracts 
validation of an approach utilizing a larval zebrafish locomotor assay 
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3.2. HPLC-based activity profiling for GABAA receptor modulators in Searsia pyroides








My contributions to this publication: Activity assessments with the zebrafish larvae locomotor assay, 
HPLC-based activity profiling of the active extract, purification and identification of the



























































































































































































HPLC-based activity profiling for GABAA receptor modulators from Searsia pyroides leaves using a 
validated larval zebrafish locomotor assay 
Table S1. d 1 - 6
No 1 2 3 4 5 6
3 d d d d d d
4 dd dd dd dd dd dd
5 d d d d d d
6
7 m m m m m m
8 m m m m m m







16 m m m m
17 m m m m
18 m m m m m
19 m m m m m
20 m m m m m
21 t t t m m m
22 m m m
23 t t t
OH
Table S2. d 1 6

























Table S3. 1 6
compound acc. mass found
[M-H]-









Figure S1. E Z 1 d
Figure S2. E Z 1 d
3.3.  Validation of UHPLC-MS/MS methods for the determination of kaempferol and its 
metabolite 4-hydroxyphenyl acetic acid, and application to blood-brain barrier and
intestinal drug permeability studies 
Journal of Pharmaceutical and Biomedical Analysis DOI:
in silico
My contributions to this publication: development and validation of the UPLC-MS/MS method in the 
RHB and , performing the intestinal transport studies with Caco-2 cells and the BBB transport 
experiments with the mono-culture HBMEC model, sample preparation and analysis, writing the 
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Nominal concentration (ng/mL) Regression parameters
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Carry-over (%) Mean Carry-over (%)
Blank sample LLOQ
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Blank sample LLOQ










Carry-over (%) Mean Carry-over (%)
Blank sample LLOQ









Carry-over (%) Mean Carry-over (%)
Blank sample LLOQ




























































Nominal concentration (ng/mL) 60.0 1600 60.0 1600
Table S19:
RHB HBSS
Nominal concentration (ng/mL) 60.0 1600 60.0 1600
Table S20: 
KMF SS stored below -65°C for 180 days 
with freshly prepared IS SS








4-HPAA SS stored below -65°C for 35 days 
with freshly prepared IS SS








VA SS stored below -65°C for 190 days 
with freshly prepared 4-HPAA SS







Table S23: in silico
















Table S23: in silico

















































in vitro in vivo
in vitro
in vitro
in vivo
in vitro
in vitro
in vivo
via in vitro
in vivo
in vitro
in vitro
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